Hanx Biopharmaceuticals Nets HK$531 Million from Hong Kong IPO Ahead of Debut

MT Newswires Live12-23 06:48

Hanx Biopharmaceuticals (HKG:3378) raised HK$531.3 million in net proceeds from its initial public offering in Hong Kong.

The final offer price was set at HK$32.00 per share, according to a Monday after-market filing with the Hong Kong Stock Exchange.

The biopharmaceutical company offered 18.3 million H-shares in the global offering.

The Hong Kong public offer was 3,074.09 times oversubscribed, with a final allocation of 1.8 million shares, or 10% of the total offering.

The international offering was 5.78 times subscribed, with a final allocation of 16.5 million shares, or 90% of the total.

Cornerstone investors, including Fund Resources Investment Holding Group, Sage Partners Master Fund, Guotai Junan Investments (Hong Kong), TFI Investment Fund SPC (Lakeside SP), Main Source Capital, YStem Holding, and Awaken Thunder Capital, were allotted a combined 2.9 million shares, representing 15.93% of the global offering, according to the filing.

Hanx Biopharmaceuticals is scheduled to debut on the Hong Kong bourse on Tuesday, Dec. 23.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593552214?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 06:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593552214","market":"hk","top_or_hot":-1,"title":"Hanx Biopharmaceuticals Nets HK$531 Million from Hong Kong IPO Ahead of Debut","media":"MT Newswires Live","content":"<html><body><p> Hanx Biopharmaceuticals (HKG:3378) raised HK$531.3 million in net proceeds from its initial public offering in Hong Kong.</p><p>The final offer price was set at HK$32.00 per share, according to a Monday after-market filing with the Hong Kong Stock Exchange.</p><p>The biopharmaceutical company offered 18.3 million H-shares in the global offering.</p><p>The Hong Kong public offer was 3,074.09 times oversubscribed, with a final allocation of 1.8 million shares, or 10% of the total offering.</p><p>The international offering was 5.78 times subscribed, with a final allocation of 16.5 million shares, or 90% of the total.</p><p>Cornerstone investors, including Fund Resources Investment Holding Group, Sage Partners Master Fund, Guotai Junan Investments (Hong Kong), TFI Investment Fund SPC (Lakeside SP), Main Source Capital, YStem Holding, and Awaken <a href=\"https://laohu8.com/S/XNET\">Thunder</a> Capital, were allotted a combined 2.9 million shares, representing 15.93% of the global offering, according to the filing.</p><p>Hanx Biopharmaceuticals is scheduled to debut on the Hong Kong bourse on Tuesday, Dec. 23.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals Nets HK$531 Million from Hong Kong IPO Ahead of Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals Nets HK$531 Million from Hong Kong IPO Ahead of Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-23 06:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hanx Biopharmaceuticals (HKG:3378) raised HK$531.3 million in net proceeds from its initial public offering in Hong Kong.</p><p>The final offer price was set at HK$32.00 per share, according to a Monday after-market filing with the Hong Kong Stock Exchange.</p><p>The biopharmaceutical company offered 18.3 million H-shares in the global offering.</p><p>The Hong Kong public offer was 3,074.09 times oversubscribed, with a final allocation of 1.8 million shares, or 10% of the total offering.</p><p>The international offering was 5.78 times subscribed, with a final allocation of 16.5 million shares, or 90% of the total.</p><p>Cornerstone investors, including Fund Resources Investment Holding Group, Sage Partners Master Fund, Guotai Junan Investments (Hong Kong), TFI Investment Fund SPC (Lakeside SP), Main Source Capital, YStem Holding, and Awaken <a href=\"https://laohu8.com/S/XNET\">Thunder</a> Capital, were allotted a combined 2.9 million shares, representing 15.93% of the global offering, according to the filing.</p><p>Hanx Biopharmaceuticals is scheduled to debut on the Hong Kong bourse on Tuesday, Dec. 23.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593552214","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593552214","pubTimestamp":1766443711,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hanx Biopharmaceuticals  raised HK$531.3 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$32.00 per share, according to a Monday after-market filing with the Hong Kong Stock Exchange.The biopharmaceutical company offered 18.3 million H-shares in the global offering.The Hong Kong public offer was 3,074.09 times oversubscribed, with a final allocation of 1.8 million shares, or 10% of the total offering.The international offering was 5.78 times subscribed, with a final allocation of 16.5 million shares, or 90% of the total.Cornerstone investors, including Fund Resources Investment Holding Group, Sage Partners Master Fund, Guotai Junan Investments , TFI Investment Fund SPC , Main Source Capital, YStem Holding, and Awaken Thunder Capital, were allotted a combined 2.9 million shares, representing 15.93% of the global offering, according to the filing.Hanx Biopharmaceuticals is scheduled to debut on the Hong Kong bourse on Tuesday, Dec.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B","BK1173":"海港与服务","BK1535":"港口运输股"},"translate_title":"Hanx Biopharmaceuticals在香港IPO上市前净赚5.31亿港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":0.9},"content_text":"Hanx Biopharmaceuticals (HKG:3378) raised HK$531.3 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$32.00 per share, according to a Monday after-market filing with the Hong Kong Stock Exchange.The biopharmaceutical company offered 18.3 million H-shares in the global offering.The Hong Kong public offer was 3,074.09 times oversubscribed, with a final allocation of 1.8 million shares, or 10% of the total offering.The international offering was 5.78 times subscribed, with a final allocation of 16.5 million shares, or 90% of the total.Cornerstone investors, including Fund Resources Investment Holding Group, Sage Partners Master Fund, Guotai Junan Investments (Hong Kong), TFI Investment Fund SPC (Lakeside SP), Main Source Capital, YStem Holding, and Awaken Thunder Capital, were allotted a combined 2.9 million shares, representing 15.93% of the global offering, according to the filing.Hanx Biopharmaceuticals is scheduled to debut on the Hong Kong bourse on Tuesday, Dec. 23.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593552214","isCrawlerRequest":true}